<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142385</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-093</org_study_id>
    <secondary_id>NCI-2016-01358</secondary_id>
    <secondary_id>AMC-093</secondary_id>
    <secondary_id>AMC-093</secondary_id>
    <secondary_id>AMC-093</secondary_id>
    <secondary_id>R21CA167652</secondary_id>
    <secondary_id>UM1CA121947</secondary_id>
    <nct_id>NCT04142385</nct_id>
  </id_info>
  <brief_title>Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men</brief_title>
  <official_title>Incidence of Human Immunodeficiency Virus (HIV) Among Indian Men Who Have Sex With Men (MSM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Udaan Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial studies the incidence of human immunodeficiency virus (HIV) infection in
      screening Indian men who have sex with men (MSM). Gathering health information over time from
      Indian MSM may help doctors determine how many Indian MSM develop new cases of HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the one-year incidence of HIV among high-risk MSM in India.

      SECONDARY OBJECTIVES:

      I. To test the feasibility and acceptability of recruiting a sample of 150 high-risk
      HIV-uninfected MSM using respondent-driven sampling (RDS) and following them every six months
      for one year.

      II. To produce preliminary descriptive data on the prevalence and incidence of human
      papillomavirus (HPV) infection and HPV-associated disease and sexually transmitted infections
      (STIs) other than HPV in HIV-seronegative MSM in India.

      III. To produce preliminary descriptive data on sexual risk behaviors with men and women, as
      well as data on other potential confounders.

      OUTLINE:

      Participants receive a questionnaire, undergo a targeted physical and anal clinical exam,
      undergo blood collection and urethral swab for STIs, and a penile skin cell and anal swab for
      cytology and HPV deoxyribonucleic acid (DNA) at months 0, 6, and 12. Participants also
      undergo high-resolution anoscopy (HRA) and penile clinical exam at month 12.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of human immunodeficiency virus (HIV)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The total number of participants with incident HIV divided by the total follow-up will be used to calculate the incidence per 100 person years. HIV status is determined by HIV rapid test and a confirmatory Western blot test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful respondent-driven sampling (RDS)</measure>
    <time_frame>3 months</time_frame>
    <description>Defined as half of the study sample enrolled and at least 50% of the responses to the questions of RDS acceptability are answered &quot;Not at all embarrassed or burdened by RDS&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful respondent-driven sampling (RDS)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as more than 80% of participants recruited through RDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of penile human papillomavirus (HPV) infection, assessed by polymerase chain reaction (PCR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Summarized using proportions and exact 95% binomial confidence interval (CI). Will be estimated for specific types and for all combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of human papillomavirus (HPV)-associated lesions of the penis</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Summarized using proportions and exact 95% binomial CI. Will be estimated for specific types and for all combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of human papillomavirus (HPV)-associated lesions of the anus</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Summarized using proportions and exact 95% binomial CI. Will be estimated for specific types and for all combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of anal human papillomavirus (HPV) infection, assessed by polymerase chain reaction (PCR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Summarized using proportions and exact 95% binomial confidence interval (CI). Will be estimated for specific types and for all combined.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Observational (health information collection)</arm_group_label>
    <description>Participants receive a questionnaire, undergo a targeted physical and anal clinical exam, undergo blood collection and urethral swab for STIs, and a penile skin cell and anal swab for cytology and HPV DNA at months 0, 6, and 12. Participants also undergo HRA and penile clinical exam at month 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cytology Specimen Collection Procedure</intervention_name>
    <description>Undergo blood, urethral swab, penile skin cell, and anal swab collection</description>
    <arm_group_label>Observational (health information collection)</arm_group_label>
    <other_name>Cytologic Sampling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Observational (health information collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Medical Examination</intervention_name>
    <description>Undergo anal and penile clinical exam</description>
    <arm_group_label>Observational (health information collection)</arm_group_label>
    <other_name>Exam</other_name>
    <other_name>Examination</other_name>
    <other_name>Medical Assessment</other_name>
    <other_name>Medical Exam</other_name>
    <other_name>Medical Inspection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical Examination</intervention_name>
    <description>Undergo targeted physical exam</description>
    <arm_group_label>Observational (health information collection)</arm_group_label>
    <other_name>Assessment</other_name>
    <other_name>Physical</other_name>
    <other_name>Physical Assessment</other_name>
    <other_name>Physical Exam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Proctoscopy with Biopsy</intervention_name>
    <description>Undergo HRA</description>
    <arm_group_label>Observational (health information collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (health information collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-seronegative MSM in Mumbai, India
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV seronegative, as documented by any licensed HIV test according to National
             Acquired Immunodeficiency Syndrome (AIDS) Control Organization (NACO) guidelines

          -  Participants report any sex with a man in the past 6 months

          -  Participants must speak Hindi, Marathi, or English

          -  Participant should not have any plans to move out of the area in the next 12 months
             and commit to attending two additional visits one at 6 months and one at 12 months

        Exclusion Criteria:

          -  Active drug or alcohol use or dependence, or other impairment that, in the opinion of
             the site investigator, would interfere with adherence to study requirements

               -  Participants with impairments that, in the opinion of the site Investigator, are
                  temporary, will be asked to return another day for enrollment

          -  Inability to provide informed consent

          -  History of a sex change operation that would preclude collection of penile or scrotal
             specimens
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Palefsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Malignancy Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joel Palefsky</last_name>
      <phone>877-827-3222</phone>
      <email>joel.palefsky@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Joel Palefsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Sharmila A. Pimple</last_name>
      <phone>91-22-24154379</phone>
      <email>pimplesa@tmc.gov.in</email>
    </contact>
    <investigator>
      <last_name>Sharmila A. Pimple</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Udaan Trust</name>
      <address>
        <city>Mumbai</city>
        <zip>401706</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Vijay Nair</last_name>
      <phone>91-22-3209-4538</phone>
      <email>airvijaynair@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Nair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

